Prospective clinical study of early diagnosis and treatment for intravasclular large B-cell lymphoma (IVL)

Prospective clinical study of early diagnosis and treatment for intravasclular large B-cell lymphoma (IVL) - Early diagnosis and treatment for IVLBCL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001309

Enrollment

Registered

2008-08-11

Start date

2007-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intravascular large B -cell lymphoma: IVL

Interventions

2/3 reduced dose CHOP therapy following rituximab on course 1. Standard dose R-CHOP therapy on course 2 to 6. HDC/AHST if possible.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, Age more than 19 2, IVL diagnosis 2-1, Pathological diagnosis or 2-2, Early clinical diagnosis who fulfilled our criteria with bone marrow and random skin biopsy 3, Informed consent

Exclusion criteria

Exclusion criteria: 1, collagen vascular disease 2, Severe infectious disease 3, Pre-treatment history for lymphoma 4, HIV+, HTLV1+ or HBV-Ag+ 5, Physician's decision of inappropriateness

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
CR rate, Adverse events, Correspondence rate between early clinical diagnosis and pathological diagnosis, Diagnostic rate of bone marrow and/or random skin biopsy, Time to treatment failure	—

Countries

Japan

Contacts

Public ContactYasufumi Masaki

Kanazawa Medical University Hematology and Immunology

yasum@kanazawa-med.ac.jp076-286-3511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026